Since December 2019, health systems worldwide have faced the pandemic caused by the new severe acute respiratory syndrome coronavirus 2. The pandemic began in China and has spread throughout the world. This new coronavirus has a high transmission capacity and elevated lethality in people over 60 years old and in those with risk factors (obesity, diabetes, and systemic arterial hypertension); those characteristics have a different proportion in each country. At present, there is no specific, effective, and safe treatment to treat this virus. In this review, an analysis is made on the differences in epidemiological aspects of the disease and its presentation in pediatric patients; the poorly-based recommendation for using an empirical combination of antimalarials plus antimicrobials as antiviral treatment; the indication of intravenous steroids; and the possible influence of antihypertensive drugs on the course of the disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.24875/BMHIM.20000166 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Collaborative Online International Learning Experience for Doctoral Nursing Students and Faculty From Three Countries: Reshaping the Educational Landscape.
Nurs Educ Perspect
October 2024
About the Authors Judith Bacchus Cornelius, PhD, RN, FAAN, ANEF, is a professor, College of Health and Human Services, University of North Carolina at Charlotte, Charlotte, North Carolina. Charlene Downing, PhD, RN, is a professor, Department of Nursing, Faculty of Health Sciences, University of Johannesburg, Johannesburg, South Africa. Adesola A. Ogunfowokan, PhD, RN, FWACN, is a professor, Community Health Nursing, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria. Nompumelelo Ntshingila, DCur(UJ), is an associate professor, Department of Nursing, Faculty of Health Sciences, University of Johannesburg. Florence Okoro, PhD, RN, is an associate professor, College of Health and Human Services, University of North Carolina at Charlotte. Ijeoma Enweana, DNP, RN, CVN, is adjunct nursing faculty, Presbyterian School of Nursing, Queens University of Charlotte, Charlotte, North Carolina. Oluwayemisi Olagunju, PhD, is senior lecturer, Department of Nursing Science, Obafemi Awolowo University. Funding was received from the University of North Carolina at Charlotte Global Learning and Internationalization Institute. For more information, contact Dr. Cornelius at
The COVID-19 pandemic presented opportunities for educational innovations and the development of intercultural learning experiences. A global health assignment guided by a collaborative online international learning pedagogy was assigned to doctoral nursing students from three different countries. Icebreaker activities, along with the Culturally You diagram, commenced the team-building process.
View Article and Find Full Text PDFCOVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time.
Rheumatol Int
December 2024
Department of General Practice N2, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
We discuss the paper recently published in Rheumatology Internationa. This article reflects on the prevalence of autoimmune rheumatic diseases (ARD) during the COVID-19 pandemic (2020-2023) and compares the same with the pre-pandemic period (2016-2019). We assume that SARS-CoV-2 triggers ARD.
View Article and Find Full Text PDFPredictors of high-flow nasal cannula (HFNC) failure in severe community-acquired pneumonia or COVID-19.
Intern Emerg Med
December 2024
Department of Respiratory Medicine and Allergology, University Hospital, Goethe University, Frankfurt, Germany.
The aim was to identify predictors for early identification of HFNC failure risk in patients with severe community-acquired (CAP) pneumonia or COVID-19. Data from adult critically ill patients admitted with CAP or COVID-19 and the need for ventilatory support were retrospectively analysed. HFNC failure was defined as the need for invasive ventilation or death before intubation.
View Article and Find Full Text PDFNew-onset cardiovascular diseases post SARS-CoV-2 infection in an urban population in the Bronx.
Sci Rep
December 2024
Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
This study investigated the incidence of new-onset cardiovascular disorders up to 3.5 years post SARS-CoV-2 infection for 56,400 individuals with COVID-19 and 1,093,904 contemporary controls without COVID-19 in the Montefiore Health System (03/11/2020 to 07/01/2023). Outcomes were new incidence of major adverse cardiovascular event (MACE), arrhythmias, inflammatory heart disease, thrombosis, cerebrovascular disorders, ischemic heart disease and other cardiac disorders between 30 days and (up to) 3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!